CH666183A5 - Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. - Google Patents
Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. Download PDFInfo
- Publication number
- CH666183A5 CH666183A5 CH3362/85A CH336285A CH666183A5 CH 666183 A5 CH666183 A5 CH 666183A5 CH 3362/85 A CH3362/85 A CH 3362/85A CH 336285 A CH336285 A CH 336285A CH 666183 A5 CH666183 A5 CH 666183A5
- Authority
- CH
- Switzerland
- Prior art keywords
- pharmaceutical composition
- coenzyme
- creatine phosphate
- muscle
- cardiac
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 230000001681 protective effect Effects 0.000 title claims description 5
- 230000000747 cardiac effect Effects 0.000 title claims description 4
- 230000002503 metabolic effect Effects 0.000 title claims 3
- 230000037149 energy metabolism Effects 0.000 title description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 56
- 239000005515 coenzyme Substances 0.000 claims description 23
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 12
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 12
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 5
- 230000002107 myocardial effect Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940035936 ubiquinone Drugs 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 7
- 229940110767 coenzyme Q10 Drugs 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 210000000518 sarcolemma Anatomy 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 238000013130 cardiovascular surgery Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940031192 coenzyme Q10 10 mg Drugs 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000003540 papillary muscle Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZCHMSSOGPAFJTM-UHFFFAOYSA-N butanedioic acid 1-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CCC(O)=O.OC(C(CC(O)=O)C(O)=O)C(O)=O ZCHMSSOGPAFJTM-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000026326 mitochondrial transport Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH3362/85A CH666183A5 (it) | 1985-08-06 | 1985-08-06 | Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. |
| DE19863625433 DE3625433A1 (de) | 1985-08-06 | 1986-07-28 | Pharmazeutische zusammensetzungen mit einer herz- und stoffwechsel-schuetzenden aktivitaet beim energetischen muskelstoffwechsel |
| GB8618589A GB2178661B (en) | 1985-08-06 | 1986-07-30 | Cardiac and muscular metabolic protecting compositions |
| IT8621394A IT1213319B (it) | 1985-08-06 | 1986-08-01 | Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. |
| NL8601979A NL8601979A (nl) | 1985-08-06 | 1986-08-01 | Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. |
| BE2/61025A BE905210A (nl) | 1985-08-06 | 1986-08-04 | Farmaceutische preparaten met cardiale en metabolische beschermende werking op het energetische spiermetabolisme. |
| JP61184973A JPS6253924A (ja) | 1985-08-06 | 1986-08-05 | 心臓および筋代謝保護剤 |
| FR868611375A FR2586352B1 (fr) | 1985-08-06 | 1986-08-06 | Compositions pharmaceutiques contenant une coenzyme du type ubiquinone, douees d'activite de protection cardiaque et metabolique sur le metabolisme energetique musculaire |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH3362/85A CH666183A5 (it) | 1985-08-06 | 1985-08-06 | Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH666183A5 true CH666183A5 (it) | 1988-07-15 |
Family
ID=4254335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH3362/85A CH666183A5 (it) | 1985-08-06 | 1985-08-06 | Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS6253924A (enrdf_load_stackoverflow) |
| BE (1) | BE905210A (enrdf_load_stackoverflow) |
| CH (1) | CH666183A5 (enrdf_load_stackoverflow) |
| DE (1) | DE3625433A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2586352B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2178661B (enrdf_load_stackoverflow) |
| IT (1) | IT1213319B (enrdf_load_stackoverflow) |
| NL (1) | NL8601979A (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19537494C2 (de) * | 1995-09-25 | 1997-10-02 | Desitin Arzneimittel Gmbh | Kreatin zum Schutz von neuralem Gewebe |
| US20040204500A1 (en) * | 2001-06-28 | 2004-10-14 | Yasuo Sugiyama | Preventives/remedies for organ functional disorders and organ dysfunction |
| DE202023001978U1 (de) | 2023-09-20 | 2023-09-29 | Penta Phi Eg | Formulierung umfassend Coenzym Q10 und Kreatin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH655005A5 (it) * | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. |
-
1985
- 1985-08-06 CH CH3362/85A patent/CH666183A5/it not_active IP Right Cessation
-
1986
- 1986-07-28 DE DE19863625433 patent/DE3625433A1/de active Granted
- 1986-07-30 GB GB8618589A patent/GB2178661B/en not_active Expired
- 1986-08-01 NL NL8601979A patent/NL8601979A/nl not_active Application Discontinuation
- 1986-08-01 IT IT8621394A patent/IT1213319B/it active
- 1986-08-04 BE BE2/61025A patent/BE905210A/nl not_active IP Right Cessation
- 1986-08-05 JP JP61184973A patent/JPS6253924A/ja active Granted
- 1986-08-06 FR FR868611375A patent/FR2586352B1/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB8618589D0 (en) | 1986-09-10 |
| IT8621394A0 (it) | 1986-08-01 |
| JPS6354690B2 (enrdf_load_stackoverflow) | 1988-10-28 |
| JPS6253924A (ja) | 1987-03-09 |
| FR2586352A1 (fr) | 1987-02-27 |
| NL8601979A (nl) | 1987-03-02 |
| FR2586352B1 (fr) | 1992-05-29 |
| GB2178661A (en) | 1987-02-18 |
| DE3625433A1 (de) | 1987-02-19 |
| BE905210A (nl) | 1986-12-01 |
| GB2178661B (en) | 1989-08-31 |
| IT1213319B (it) | 1989-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5545614A (en) | Controlling nitrogen oxide concentrations to modulate skeletal muscle contraction | |
| US20020094996A1 (en) | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | |
| ITRM990467A1 (it) | Composizione per la prevenzione degli affaticamenti muscolari e per migliorare il rendimento energetico muscolare. | |
| AU675412B2 (en) | Method of treating HIV infection | |
| DE69125216D1 (de) | Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen | |
| DE69915143D1 (de) | Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen | |
| WO1996031217A9 (en) | Inhibiting retroviral replication | |
| ITRM20000323A1 (it) | Integratore alimentare potenziante il metabolismo energetico muscolare, comprendente una alcanoil l-carnitina e ribosio. | |
| CH670763A5 (enrdf_load_stackoverflow) | ||
| Agarwal et al. | Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep | |
| JP3622985B2 (ja) | マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法 | |
| BR9910628A (pt) | Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária | |
| CH666183A5 (it) | Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. | |
| EP0437929B1 (en) | Use of diadenosine-5',5'''-p1,p4-tetraphosphate for the manufacture of a medicament for the treatment of heart disease | |
| WO1997002822A1 (fr) | Medicament destine a soigner les affections du cerveau | |
| EP0530220B1 (en) | Pharmaceutical composition | |
| EP0352746A2 (en) | A composition for enhancing oxygen availability or relieving hypoxia in a mammal | |
| JP2002536325A (ja) | 疾患を治療するためのｌ−アルギニン基盤の処方およびその使用方法 | |
| CA2543252A1 (en) | Use of bh4 for the treatment of respiratory diseases | |
| US4701462A (en) | Method for prevention of hypertension | |
| EP2586776A1 (en) | Soft cationic mitochondrial uncouplers | |
| BRPI0016329B8 (pt) | bis-indolilmaleimidas substituídas para inibição de proliferação de células, seu processo de preparação e seu uso, bem como composição farmacêutica. | |
| EP1671630A2 (en) | L-Arginine based formulations for treating diseases and methods of using the same | |
| YOSHITOSHI et al. | Efficacy of Levocarnitine Chloride (LC-80) in Treatment of Ischemic Heart Diseases by the Serial Multistage Treadmill Exercise Testing A Multicenter Double-Blind Group-Comparison Study | |
| HU200941B (en) | Process for producing pharmaceutical compositions comprising n-carboxyalkyldipeptide derivatives as active ingredient and suitable for treating coronary diseases and diseases of cerabral vascular system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |